ABSTRACT
Now that prohibitions against stem cell research are relaxing, it is time for the field to move forward with the advances that promise to eliminate so much human suffering. However, it would be naive to ignore the fact that regenerative medicines pose a whole new set of challenges to an industry sector that for decades has geared itself to the deve
TABLE OF CONTENTS
part |2 pages
SECTION 1 Introduction
part |2 pages
SECTION 2 Finance
part |2 pages
SECTION 3 Business Models
part |2 pages
SECTION 4 Intellectual Property
part |2 pages
SECTION 5 Regulatory Landscape
part |2 pages
SECTION 6 Reimbursement
part |2 pages
SECTION 7 Insurance and Risk Management